Leukemia stem cells (LSCs) pose a significant challenge in treating acute myeloid leukemia (AML) due to their resistance to ...

"The first thing in my head was, 'Oh my gosh, I don't get to go to Taylor Swift,'" Hannah Everson said of learning her cancer ...

The FDA granted orphan designation to Janssen Research & Development’s bleximenib as a treatment of acute myeloid leukemia, according ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical company with a broad ...

In the past decade, we have made significant progress in understanding the biology of acute myeloid leukemia (AML) and ALL, including studying the underlying immune systems at play (3). This has led ...

The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute ...

In the last decade, tremendous advances have revolutionized the biological landscape of acute myeloid leukemia (AML). The application of sophisticated molecular biology tools has unveiled a plethora ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...

With a new four-year, $1.3 million grant from the U.S. Department of Veterans Affairs, researchers at Case Western Reserve ...

Moleculin Biotech ( (MBRX) ) just unveiled an update. Moleculin Biotech has released the transcript of its recent Virtual ...

With a new four-year, $1.3 million grant from the U.S. Department of Veterans Affairs, researchers at Case Western Reserve ...

A 6 year old arkansan battling leukemia was recognized at the 6th annual lift againt leukemia today.T-cell acute ...